Urinary Angiostatin - A Novel Putative Marker of Renal Pathology Chronicity in Lupus Nephritis*

There is a critical need to identify biomarkers for Systemic Lupus Erythematosus (SLE) which has a high prevalence of renal failure. When urine from patients with lupus nephritis was recently screened for the levels of ∼280 molecules using an exploratory array-based proteomic platform, elevated angiostatin levels were noted. Angiostatin is a bioactive fragment of plasminogen, and has been known to have modulatory function in angiogenesis and inflammation. The significant elevation in urinary angiostatin was next validated in an independent cohort of SLE patients (n = 100) using ELISA. Among patients with SLE, urine angiostatin was significantly increased in active SLE compared with inactive SLE, correlating well with the SLEDAI disease activity index and SLICC renal activity score (r = 0.66, p < 0.0001). ROC curve analysis further confirmed that urinary angiostatin had the capacity to discriminate patients with active SLE from those with inactive disease. Patients with Class IV lupus nephritis exhibited the highest levels of urinary angiostatin. Immunohistochemistry staining localized angiostatin expression to the renal tubular cells in these patients. Finally, when paired urine-kidney samples procured concurrently from patients with LN were next examined, urine angiostatin levels correlated strongly with the renal pathology chronicity index, but not with the activity index. Given that Class IV lupus nephritis and renal pathology chronicity changes forebode poor renal and patient survival, urinary angiostatin emerges as a novel noninvasive marker of renal disease in SLE. Longitudinal studies are in progress to further assess the disease-predictive potential of urinary angiostatin.

[1]  H. Nagaraja,et al.  Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. , 2005, Kidney international.

[2]  L. Davis,et al.  Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. , 2007, The Journal of clinical investigation.

[3]  Chandra Mohan,et al.  Elevated Urinary VCAM-1, P-Selectin, Soluble TNF Receptor-1, and CXC Chemokine Ligand 16 in Multiple Murine Lupus Strains and Human Lupus Nephritis1 , 2007, The Journal of Immunology.

[4]  M. Hussein,et al.  Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings , 2010, Clinical and Experimental Nephrology.

[5]  L. Gnudi,et al.  Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. , 2000, Journal of the American Society of Nephrology : JASN.

[6]  I. Bruce,et al.  Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. , 2008, Arthritis and rheumatism.

[7]  V. Kelley,et al.  Distinct roles of CSF-1 isoforms in lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.

[8]  C. Fiehn,et al.  Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment , 2003, Annals of the rheumatic diseases.

[9]  N. Futrakul,et al.  Altered vascular homeostasis in chronic kidney disease. , 2008, Clinical hemorheology and microcirculation.

[10]  H. Nagaraja,et al.  Biomarkers of lupus nephritis determined by serial urine proteomics. , 2008, Kidney international.

[11]  D. Witte,et al.  Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[12]  C. Putterman,et al.  Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis , 2012, Arthritis Research & Therapy.

[13]  L. Magder,et al.  Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis , 2009, The Journal of Rheumatology.

[14]  Y. Marunaka.  Hormonal and osmotic regulation of NaCl transport in renal distal nephron epithelium. , 1997, The Japanese journal of physiology.

[15]  F. Castellino,et al.  The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Hara,et al.  Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. , 2006, Kidney international.

[17]  G. Mastroianni-Kirsztajn,et al.  Are Urinary Levels of Free Light Chains of Immunoglobulins Useful Markers for Differentiating between Systemic Lupus Erythematosus and Infection? , 2008, Nephron Clinical Practice.

[18]  Y. Molad,et al.  Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. , 2002, Clinical and experimental rheumatology.

[19]  S. Marks,et al.  Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis , 2010, Pediatric Nephrology.

[20]  J. Cameron,et al.  Lupus Nephritis , 1959, Clinics in rheumatic diseases.

[21]  S. Thorsen,et al.  Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin. , 1981, The Biochemical journal.

[22]  Yi Fu,et al.  Ectopic ATP synthase in endothelial cells: a novel cardiovascular therapeutic target. , 2010, Current pharmaceutical design.

[23]  R. Aisina,et al.  Structure and function of plasminogen/plasmin system , 2014, Russian Journal of Bioorganic Chemistry.

[24]  John R Raymond,et al.  Urine biomarkers predict the cause of glomerular disease. , 2007, Journal of the American Society of Nephrology : JASN.

[25]  B. Rovin,et al.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study , 2009, Arthritis research & therapy.

[26]  D. Gladman,et al.  Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. , 2008, Arthritis and rheumatism.

[27]  C. Putterman,et al.  Urinary Biomarkers in Lupus Nephritis , 2011, Clinical reviews in allergy & immunology.

[28]  C. Mok.  Prognostic factors in lupus nephritis , 2005, Lupus.

[29]  W. Hauswirth,et al.  Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. , 2009, American journal of physiology. Renal physiology.

[30]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[31]  T. Hirano,et al.  Urinary levels of IL-6 in patients with active lupus nephritis. , 1993, Clinical nephrology.

[32]  R. Edwards,et al.  Urinary proteomic profiles distinguish between active and inactive lupus nephritis. , 2006, Rheumatology.

[33]  Jun Ying,et al.  Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis , 2009, Pediatric Research.

[34]  Chandra Mohan,et al.  Urine Proteome Scans Uncover Total Urinary Protease, Prostaglandin D Synthase, Serum Amyloid P, and Superoxide Dismutase as Potential Markers of Lupus Nephritis , 2010, The Journal of Immunology.

[35]  Y. Sugisaki,et al.  Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. , 2001, The American journal of pathology.

[36]  X. Ao,et al.  Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2011, Cytokine.

[37]  J. Klippel,et al.  Prognostic factors in lupus nephritis. Contribution of renal histologic data. , 1983, The American journal of medicine.

[38]  D. Webb,et al.  Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. , 2009, American journal of physiology. Renal physiology.

[39]  K. Shitara,et al.  and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .

[40]  D. Isenberg,et al.  Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. , 2010, Rheumatology.

[41]  William Arbuthnot Sir Lane,et al.  Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. , 1994, Cold Spring Harbor symposia on quantitative biology.